University of Chicago

URGENT! We're Running Out of time to Save Lives and Stop Gun Violence in Chicago

Wednesday, September 22, 2021 - 6:47pm

Key point: Rigorous studies showed that young adult employment in the summer reduced violence and crime by the youth participants.

Key Points: 
  • Key point: Rigorous studies showed that young adult employment in the summer reduced violence and crime by the youth participants.
  • Violence by summer youth employment participants was reduced for the following year or longer.
  • Congress has a chance to stop violence among youth and young adults.
  • The reduction and stopping of violence will not happen overnight, but over three years, violence will be significantly reduced.

Ocular Therapeutix™ Appoints Merilee Raines to Its Board of Directors

Wednesday, September 22, 2021 - 1:00pm

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Merilee Raines to the Companys Board of Directors effective September 20, 2021.

Key Points: 
  • Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Merilee Raines to the Companys Board of Directors effective September 20, 2021.
  • We are excited to welcome Merilee to our Board of Directors, said Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix.
  • Her guidance and input will be invaluable as we seek to grow Ocular into a strategic leader in the ophthalmology space.
  • Ms. Raines is also an experienced independent board director and currently serves as a member of the Board of Directors of Transmedics Group, Inc. (NASDAQ:TMDX), Watts Water Technologies, Inc. (NYSE:WTS) and Excelitas Technologies Corporation, a private company.

Triumvira Doses First Patient with Novel T Cell Therapy in TACTIC-2 Clinical Trial

Monday, September 20, 2021 - 1:00pm

Triumvira, a clinical-stage company, is developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid and liquid tumors.

Key Points: 
  • Triumvira, a clinical-stage company, is developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid and liquid tumors.
  • The companys proprietary T cell Antigen Coupler (TAC) platform technology activates natural T cell functions differently from other cell therapies such as Chimeric Antigen Receptor T cell (CAR-T) and engineered T cell receptor therapies.
  • The initiation of our TACTIC-2 trial represents a significant milestone for Triumvira and an opportunity to establish clinical proof of concept for our TAC technology.
  • With this trial, Triumvira is the first company in the U.S. to dose a patient with a therapy manufactured with Lonzas Cocoon Platform.

Awakn Life Sciences Reports Second Quarter 2021 Financial Results and Business Highlights

Wednesday, September 15, 2021 - 12:30pm

Toronto, Ontario--(Newsfile Corp. - September 15, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, today is reporting its financial results and business highlights for the three and six months ended July 31, 2021.

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - September 15, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, today is reporting its financial results and business highlights for the three and six months ended July 31, 2021.
  • All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars, unless otherwise specified.
  • Anthony Tennyson, Chief Executive Officer of Awakn Life Sciences, commented, "Our team has achieved many accomplishments in a short period of time since going public in June of 2021.
  • About Awakn Life Sciences Corp.
    Awakn Life Sciences is a biotechnology company with clinical operations, researching, developing, and delivering psychedelic medicine to better treat Addiction.

New Report Shows 89% of Diabetics Worry About Broken Insulin Vials

Wednesday, September 15, 2021 - 2:00pm

AUBURN, Ala., Sept. 15, 2021 (GLOBE NEWSWIRE) -- SiO2 Materials Science , a privately owned U.S.-based advanced materials science company, today released the findings from its new report: The Impact of Broken Insulin Vials On Diabetics .

Key Points: 
  • AUBURN, Ala., Sept. 15, 2021 (GLOBE NEWSWIRE) -- SiO2 Materials Science , a privately owned U.S.-based advanced materials science company, today released the findings from its new report: The Impact of Broken Insulin Vials On Diabetics .
  • From June 30 to July 8, 2021, 1,000 American adults with Type 2 diabetes who take insulin through a syringe injection were surveyed.
  • 56% regularly worry about breaking, cracking, or damaging insulin, and 33% are somewhat worried.
  • 68% have had a broken vial cause them to miss an insulin treatment.

The Vistria Group Promotes Key Partners and Announces Team Addition as Firm Continues Strong Momentum

Tuesday, September 14, 2021 - 9:20pm

CHICAGO, Sept. 14, 2021 /PRNewswire/ -- The Vistria Group, a purpose driven investment firm, today announced the promotion and addition of key team members.

Key Points: 
  • CHICAGO, Sept. 14, 2021 /PRNewswire/ -- The Vistria Group, a purpose driven investment firm, today announced the promotion and addition of key team members.
  • Kip Kirkpatrick, Co-CEO and Senior Partner at The Vistria Group, added: "Jon has been a key contributor and leader on our growing healthcare team including the recent successful recapitalization of CareMetx.
  • We are excited to announce these advancements as we continue to build The Vistria Group."
  • The Vistria Group is a Chicago-based next generation private investment firm that operates at the intersection of purpose and profit.

AccuraDX Launches Research Kits to Enable Genome-Wide View of Transcription in Cells

Monday, September 13, 2021 - 1:00pm

(Image credit: AccuraDX)

Key Points: 
  • (Image credit: AccuraDX)
    The one-stop kit enables researchers to perform single-stranded DNA (ssDNA) labeling and enrichment in bulk live cells and fresh or frozen tissues.
  • It can be applied to live cells, frozen tissues or even live animals and can provide temporal information as well.
  • AccuraDX is the exclusive licensee of the technology and there are no other kits available to perform KAS-seq on the market.
  • AccuraDX is an early-stage biotech company developing genomics technologies such as KAS-seq and Keth-seq for research tools and clinical applications.

New Report Finds 59 Drugs Have Been Recalled Due to Glass-Related Issues Since 2014

Monday, August 30, 2021 - 10:26pm

The report then identified 59 instances where drugs were recalled due to glass-related issues between January 2014 and July 2021.

Key Points: 
  • The report then identified 59 instances where drugs were recalled due to glass-related issues between January 2014 and July 2021.
  • The causes identified include recalls for delamination, particulate matter, breakage, ethylene oxide residuals and adhesive issues.
  • "This year we've already seen 18 recalls due to glass-related problems," said Lawrence Ganti, President at SiO2 Materials Science.
  • This report confirms our belief that it's time for the pharma industry to rethink the use of glass."

World-Renowned Philosopher Martha Nussbaum Supports New York Elephant Rights Case

Tuesday, August 24, 2021 - 8:20pm

NEW YORK, Aug. 24, 2021 /PRNewswire/ --World-renowned philosopher and University of Chicago Law School Professor Martha C. Nussbaum has submitted an amicus brief to the New York Court of Appeals in support of a habeas corpus petition filed by the Nonhuman Rights Project (NhRP) to free an elephant from the Bronx Zoo to an elephant sanctuary.

Key Points: 
  • NEW YORK, Aug. 24, 2021 /PRNewswire/ --World-renowned philosopher and University of Chicago Law School Professor Martha C. Nussbaum has submitted an amicus brief to the New York Court of Appeals in support of a habeas corpus petition filed by the Nonhuman Rights Project (NhRP) to free an elephant from the Bronx Zoo to an elephant sanctuary.
  • Happy is a 50-year-old Asian elephant who has been held in captivity since 1977 in a one-acre exhibit in the Bronx Zoo, which is managed by the Wildlife Conservation Society.
  • For a detailed timeline of Happy's case, court filings, and decisions, visit this page.
  • 2020-02581)
    The Nonhuman Rights Project is the only civil rights organization in the United States working through litigation, legislation, and education to secure fundamental rights for nonhuman animals.

Capstone Development Partners and Harrison Street Awarded Best Public-Private Partnership Development for Woodlawn Residential and Dining Commons at University of Chicago

Thursday, July 29, 2021 - 12:00pm

Woodlawn Residential and Dining Commons provides 1,300 UChicago students and staff with an on-campus home in an engaging, enriching community, offering 19,500 sq.

Key Points: 
  • Woodlawn Residential and Dining Commons provides 1,300 UChicago students and staff with an on-campus home in an engaging, enriching community, offering 19,500 sq.
  • Woodlawn Residential and Dining Commons was completed in June 2020 and opened for the 2020-2021 academic year.
  • Woodlawn Commons was developed by Capstone in a P3 collaboration with the University of Chicago and was financed with 100% equity through Capstone's P3+ financing program with Harrison Street.
  • Capstone also received its fourth Best Public-Private Partnership Development award in 2019 for its New Residence Hall and Dining Commons at University of Massachusetts Boston.